PMID: 9554538Apr 29, 1998Paper

The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia

Cancer
A O Hoff, R Vassilopoulou-Sellin

Abstract

Tumor hypoglycemia can be recurrent and severe enough to interfere with definitive antineoplastic treatment. Therefore, rapid commencement of effective therapy is essential. This is best accomplished by identifying which of the hypoglycemic processes is involved, as treatments differ. Some patients present with hypoglycemia and liver metastases; among them, only a few develop hypoglycemia as a result of a failure of hepatic glucose production. Most develop hypoglycemia as a result of an insulin-mediated process--either the secretion of insulin by an islet-cell tumor or the secretion of insulin-like growth factor-II by an extrapancreatic tumor. Administration of glucagon can rapidly make the two groups distinguishable, thus allowing institution of therapy and prompt symptomatic control of hypoglycemia. The charts of seven patients with tumor hypoglycemia and liver metastases who had a glucagon stimulation test (serial glucose measurements after a 1 mg infusion of glucagon) as part of the workup for hypoglycemia were retrospectively reviewed. Those patients whose test revealed a rise in serum glucose of >30 mg/ dL were subsequently treated as outpatients, with a continuous glucagon infusion delivered by a portable pump. Three pat...Continue Reading

Citations

Sep 1, 2006·PLoS Medicine·Ronald C W MaJean L F Woo
Jan 1, 2011·BMJ Case Reports·Leena Krishnan, John Clark
Sep 3, 2010·Mayo Clinic Proceedings·Lorraine C Pelosof, David E Gerber
Apr 7, 2009·Journal of Pain and Symptom Management·Kirsty Scott
Apr 16, 2013·Best Practice & Research. Clinical Gastroenterology·George Kanakis, Gregory Kaltsas
Aug 12, 2014·Orvosi hetilap·János VadászAttila Zalatnai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Islet Cell (Keystone)

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arise in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on islet cell carcinoma in this feed.

Carcinoma, Islet Cell

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arises in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Carcinoma here.

Adenoma, Islet Cell

Islet Cell Adenoma arises in the islet cells, which are insulin producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Adenoma here.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

© 2022 Meta ULC. All rights reserved